Lorem ipsum dolor sit amet

Nanocarriers

Formed by a lipid bilayer membrane, designed to deliver drugs to tumors. They reach the tumor via the bloodstream and migrate through leaky tumor vessels.
However, only a small fraction of the liposomes reaches the tumor and only partially releases the drug, meaning it does not become fully bioavailable. At the same time, significant amounts of the liposomes are trapped in the liver and spleen. For these reasons, conventional liposomes have not achieved improved antitumor efficacy.

Thermosome’s novel thermosensitive liposomes (TSL) actively release the drug only where needed: locally in the tumor.
Thermosome’s TSLs contain a novel, proprietary phospholipid called DPPG2. DPPG2 forms liposomes that are stable at body temperature, but release the drug quickly in the heated tumor area.

Formed by a lipid bilayer membrane, designed to deliver drugs to tumors. They reach the tumor via the bloodstream and migrate through leaky tumor vessels.
However, only a small fraction of the liposomes reaches the tumor and only partially releases the drug, meaning it does not become fully bioavailable. At the same time, significant amounts of the liposomes are trapped in the liver and spleen. For these reasons, conventional liposomes have not achieved improved antitumor efficacy.

Thermosome’s novel thermosensitive liposomes (TSL) actively release the drug only where needed: locally in the tumor.
Thermosome’s TSLs contain a novel, proprietary phospholipid called DPPG2. DPPG2 forms liposomes that are stable at body temperature, but release the drug quickly in the heated tumor area.

The patient lies in a medical device that uses image-guidance for precise local heating known as hyperthermia, which selectively heats the tumor area to about 41°C. Once the target temperature is reached, Thermosome’s TSLs are infused intravenously. TSLs instantly release the drug into the blood vessels of the heated tumor, reaching very high intravascular drug concentrations. The drug then diffuses into the surrounding tumor, achieving up to 15-fold higher local drug concentrations compared to the infusion of non-liposomal drugs. This dramatically enhances treatment efficacy.